These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 33103462)

  • 1. Amorphous systems for delivery of nutraceuticals: challenges opportunities.
    Tomar D; Singh PK; Hoque S; Modani S; Sriram A; Kumar R; Madan J; Khatri D; Dua K
    Crit Rev Food Sci Nutr; 2022; 62(5):1204-1221. PubMed ID: 33103462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug.
    Lakshman JP; Cao Y; Kowalski J; Serajuddin AT
    Mol Pharm; 2008; 5(6):994-1002. PubMed ID: 19434852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amorphous drug delivery systems: molecular aspects, design, and performance.
    Kaushal AM; Gupta P; Bansal AK
    Crit Rev Ther Drug Carrier Syst; 2004; 21(3):133-93. PubMed ID: 15248808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
    Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of poorly soluble compounds by amorphous solid dispersions.
    Lee TW; Boersen NA; Hui HW; Chow SF; Wan KY; Chow AH
    Curr Pharm Des; 2014; 20(3):303-24. PubMed ID: 23651395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in co-amorphous drug formulations.
    Dengale SJ; Grohganz H; Rades T; Löbmann K
    Adv Drug Deliv Rev; 2016 May; 100():116-25. PubMed ID: 26805787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-amorphous systems for the delivery of poorly water-soluble drugs: recent advances and an update.
    Han J; Wei Y; Lu Y; Wang R; Zhang J; Gao Y; Qian S
    Expert Opin Drug Deliv; 2020 Oct; 17(10):1411-1435. PubMed ID: 32683996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of metabolism-permeability in enhancing the oral bioavailability of curcumin in excipient-free solid dispersions co-formed with piperine.
    Wang R; Han J; Jiang A; Huang R; Fu T; Wang L; Zheng Q; Li W; Li J
    Int J Pharm; 2019 Apr; 561():9-18. PubMed ID: 30817985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into co-amorphous systems in therapeutic drug delivery.
    Singh R; Joshi V; Mehetre N; Sangamwar AT
    Ther Deliv; 2021 Mar; 12(3):245-265. PubMed ID: 33745286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current applications of solid lipid nanoparticles and nanostructured lipid carriers as vehicles in oral delivery systems for antioxidant nutraceuticals: A review.
    Gunawan M; Boonkanokwong V
    Colloids Surf B Biointerfaces; 2024 Jan; 233():113608. PubMed ID: 37925866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refining stability and dissolution rate of amorphous drug formulations.
    Grohganz H; Priemel PA; Löbmann K; Nielsen LH; Laitinen R; Mullertz A; Van den Mooter G; Rades T
    Expert Opin Drug Deliv; 2014 Jun; 11(6):977-89. PubMed ID: 24754747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amorphous solid dispersion technique for improved drug delivery: basics to clinical applications.
    Mishra DK; Dhote V; Bhargava A; Jain DK; Mishra PK
    Drug Deliv Transl Res; 2015 Dec; 5(6):552-65. PubMed ID: 26306524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Nutraceutical Bioavailability Classification Scheme: Classifying Nutraceuticals According to Factors Limiting their Oral Bioavailability.
    McClements DJ; Li F; Xiao H
    Annu Rev Food Sci Technol; 2015; 6():299-327. PubMed ID: 25705933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the use of spray congealing to produce solid dispersions with enhanced indomethacin bioavailability: In vitro characterization and in vivo study.
    Bertoni S; Albertini B; Ferraro L; Beggiato S; Dalpiaz A; Passerini N
    Eur J Pharm Biopharm; 2019 Jun; 139():132-141. PubMed ID: 30910731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.
    Qian F; Huang J; Hussain MA
    J Pharm Sci; 2010 Jul; 99(7):2941-7. PubMed ID: 20127825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
    Meng F; Gala U; Chauhan H
    Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermal Stability of Amorphous Solid Dispersions.
    Jelić D
    Molecules; 2021 Jan; 26(1):. PubMed ID: 33466393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ternary solid dispersions: classification and formulation considerations.
    Borde S; Paul SK; Chauhan H
    Drug Dev Ind Pharm; 2021 Jul; 47(7):1011-1028. PubMed ID: 33818224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches.
    Fakes MG; Vakkalagadda BJ; Qian F; Desikan S; Gandhi RB; Lai C; Hsieh A; Franchini MK; Toale H; Brown J
    Int J Pharm; 2009 Mar; 370(1-2):167-74. PubMed ID: 19100319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.